When CDK4/6 inhibitors (Palbociclib, Abemaciclib, and Ribociclib) were introduced to the clinic, they represented a real breakthrough for the treatment of HR+/HER2- luminal BC patients. This evidence concerns the gene CDK4 and breast cancer.